Brief: Kintor Pharma Announces Completion Of Subject Enrollment And Dosing In Phase I Clinical Trial Of AR-PROTAC(Gt20029) In The US
27/10/2022 17:10
Oct 27 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK :
* KINTOR PHARMA ANNOUNCES COMPLETION OF SUBJECT ENROLLMENT
AND
DOSING IN PHASE I CLINICAL TRIAL OF AR-PROTAC(GT20029) IN THE US
Source text for Eikon: ID:nPn1xKZCfa
Further company coverage: 9939.HK
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint